Fluence Energy, Inc. Announces Closing of Offering of $400.0 Million of Convertible Senior Notes due 2030 13-12-2024, 04:01

Technicolor Creative Studios: Strengthening of the 7-02-2023, 14:24

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26